Cargando…
Interleukin-15 is required for immunosurveillance and immunoprevention of HER2/neu-driven mammary carcinogenesis
INTRODUCTION: We previously demonstrated that HER2/neu-driven mammary carcinogenesis can be prevented by an interleukin-12 (IL-12)-adjuvanted allogeneic HER2/neu-expressing cell vaccine. Since IL-12 can induce the release of interleukin-15 (IL-15), in the present study we investigated the role playe...
Autores principales: | Croci, Stefania, Nanni, Patrizia, Palladini, Arianna, Nicoletti, Giordano, Grosso, Valentina, Benegiamo, Giorgia, Landuzzi, Lorena, Lamolinara, Alessia, Ianzano, Marianna L., Ranieri, Dario, Dall’Ora, Massimiliano, Iezzi, Manuela, De Giovanni, Carla, Lollini, Pier-Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4462012/ https://www.ncbi.nlm.nih.gov/pubmed/25997501 http://dx.doi.org/10.1186/s13058-015-0588-x |
Ejemplares similares
-
OX40 triggering concomitant to IL12-engineered cell vaccine hampers the immunoprevention of HER2/neu-driven mammary carcinogenesis
por: Nanni, Patrizia, et al.
Publicado: (2018) -
Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice
por: Ianzano, Marianna L., et al.
Publicado: (2013) -
Cancer immunoprevention: from mice to early clinical trials
por: Palladini, Arianna, et al.
Publicado: (2018) -
Vaccines against human HER2 prevent mammary carcinoma in mice transgenic for human HER2
por: De Giovanni, Carla, et al.
Publicado: (2014) -
Preclinical Therapy of Disseminated HER-2(+) Ovarian and Breast Carcinomas with a HER-2-Retargeted Oncolytic Herpesvirus
por: Nanni, Patrizia, et al.
Publicado: (2013)